Member Info for TC101

http://www.lombardmedical.com/pwpcontrol.php?pwpID=6292 RNS file path...makes for interesting reading and my thoughts about FDA asking more questions which in turn will delay the outcome to Q3 seems to have come true! Keep the faith!

I've read the process on how the FDA and approvals work. To summarize, with each module they have submitted, the FDA have 3months to review and approve. However if the FDA has any questions, then LMT have 2 months to respond back with additional evidence the FDA may want. This happened with module 4 (see there annual report for 2010). I reckon the FDA have asked to see some more information on module 6 (the final one we need) so they will push out the date for approval to potentially q3 at the latest! If we do get the approval, not doubt the sp will go up, but LMT will need to start selling this device in the states. They have all the sales and marketing teams lined up in america (the have a office there) so the real value will come when this takes off. If it does, then we have the next big market...China then India!

I suspect the Greek bailout which they need to convince there creditors to accepts a 60% write down hasnt been sorted yet so confidence is low. They have a deadline at 8pm today to sort themselves out and if they dont, they will default and that will screw up everybody! However when the price has gone up recently, there are quite a few heavy investors who have millions of LMT shares, so when the SP does go up, they start to off load which make the SP go down. Check the trades.....people are selling 1 million blocks of shares and have been for a couple of months! I'll do some digging and let you know what i find out! Keep the faith!

Approval is meant to happen Q1/Q2...if the FDA have more questions then it could be q3. As for the price going up, there was an article from an analyst who gave this a buy rating at a target price of 1.9p

Will it stay above a 1p?

The whole market seems to be up. However has someone heard something about the final approval? No doubt there will be some eurozone news soon which will push the price back down as they can't seem to sort out the mess they're in

I've never given any tips on here and none about S&F so your thanking the wrong person. And no i don't work for LMT! How is posting there RNS's misleading. Check the previous logs on here and you'll find that at no point have i given anyone misleading info. THe info that does get posted comes from their site......so grow up! In addition, if you haven't bought any of these shares, WTF are you doing on this particular stock? Thanks for the KO tip...great buy doctordutch!

Amsterdam, S&F? How is that news obvious? It is not like i posted a few weeks after it was released by LMT as it was posted on the day it was communicated. If this is the doctordutch from leeds then well, you bought in at the wrong price so perhaps you should read the obvious news that is being posted!

Lombard Medical Technologies PLC announced that data presented at the VEITH symposium in New York (November16-20), a international conference for vascular surgeons, has shown that its endovascular stent graft Aorfix has the potential to treat a larger patient population than competing devices, including both standard and difficult to treat cases of Abdominal Aortic Aneurysms (AAAs). Dr Mark Fillinger of Dartmouth Hitchcock Medical Centre, New Hampshire, presented an update on the US Pythagoras trial of Aorfix, the largest trial in the world having patients with highly tortuous aortic and iliac anatomy. The trial consists of two groups of patients. The study group of 150 cases with aortic neck angles > 60° and a 'roll-in' group of 62 patients with aortic neck angles < 60°. In his paper, Dr Fillinger presented data from the roll-in group and reported excellent results including; No cases where graft failed to seal against the artery wall and no cases where the graft leaked at either 30 days or 1 year postoperatively; The absence of any reported graft migration or fracture at either 30 days or 1 year; Sac shrinkage of more than 5 mm or no change in sac growth was shown in 100% of cases.

Interim results for the six months ended 30 June 2011 U.S. trial data submitted to FDA London, UK, 30 August 2011 - Lombard Medical Technologies PLC ("Lombard Medical", "LMT" or "the Company"), a medical device company focused on device solutions for the $1.1 billion per annum abdominal aortic aneurysm ("AAA") repair market, today announces its unaudited interim results for the six months ended 30 June 2011. Operational highlights · · Total revenues increased 26% to £1.8 million (H1 2010: £1.4 million) · U.S. clinical trial complete and final pre-market approval ("PMA") submission made on 5 August 2011 · Four of six Aorfix™ PMA modules now approved · European sales organisation strengthened: o Highly experienced Director of Central Europe appointed o Business Managers recruited for Italy and Spain o Third German sales executive appointed · Experienced U.S. medical device executive appointed Chief Operating Officer to: o Oversee operations and product development o Deliver manufacturing cost efficiencies · Manufacture of stent grafts for commercial use commenced at Prestwick facility · Aorfix™ development projects for a new generation delivery system and expanded size range progressing in line with Company expectations Financial highlights · £27.2 million raised from two-tranche placing, subscription and offer: o First tranche of £13.0 million (£12.2 million net of expenses) received May 2011 o Second tranche of £14.2 million (£13.6 million net of expenses) to be received following FDA approval of Aorfix™ · Commercial revenues increased 27% to £1.7 million (H1 2010: £1.3 million) · Gross margin increased to 53% (H1 2010: 46%) · Operating loss up £0.8 million to £5.0 million (H1 2010: £4.2 million) · Loss after taxation for the period up 18% to £4.4 million (H1 2010: £3.7 million) · Net cash of £12.1 million as at 30 June 2011 Commenting on the results, Simon Hubbert, Chief Executive of Lombard Medical, commented: "Lombard Medical has made important progress towards bringing our lead product to market in the U.S. and to putting the Company on the path to long-term revenue growth and profitability. We secured funding which is enabling us to deliver our strategy for Aorfix™, including building up a specialist sales team, ensuring sufficient manufacturing capacity and moving ahead with product innovation. We have seen the benefits of targeting major markets through our own dedicated sales force in Germany and the UK and will build on this momentum there and in other markets. The final submission to the FDA was made earlier this month and we look forward to bringing the substan

Go to google you can download there report. Valuation: 1.47 pence per share A DCF model taken out to 2017, using a 5% long-term growth rate and standard 12.5% WACC and based on US Aorfix launch in 2012 yields an NPV of £88m, or 1.47 pence per share based on the 2012 year-end share count. This compares with Lombard’s current market capitalisation of £28m or 0.7 pence per share.

Thanks for the info! Well everything appears to be on track although the FDA are taking their time to approve the 4th and 5th module. I think that hinders innovation! Try this site: http://www.edisoninvestmentresearch.co.uk/research/company/Lombard-Medical-Technologies Like that fact we are trying to get 30% of the market and if approved they can make all different sizes to increase its appeal!

Anyone heard on the grapevine if we on on track for the Final (and most important) FDA submission is still on track?

This baby is way over due in my book! Lets hope there are no more hurdles coming our way! With the amount of funding that was approved at the AGM, i would be surprised if they ever ask for money again. This funding should take them past FDA final approval and launch sales in the US and Japan!

I have confidence that the product will do well ........when the remaining FDA modules are approved! Until that happens this sp will remain low. In addition the funding once approved by shareholders at the AGM will dilute the sharse even further so i personally don't expect to see any movement on this sp for a while now! keep the faith!

4th and 5th approvals should increase sp although could be in Q3/Q4 until we hear how well they have gone. FDA approvals can take up to 9 mths!!

If i'm reading it right they have most of the funding sorted although may ask 'normal' shareholders for 2.2 million. and charge us 40% less of the price as it stands today 1.33 (so 0.7ish).

London, UK, 20 April 2011 - Lombard Medical Technologies PLC ("Lombard Medical", or "the Company"), a medical devices company focused on device solutions for the $1.1 billion dollar abdominal aortic aneurysm repair market,today announces its results for the year ended 31 December 2010. Operating Highlights Aorfix™ European Commercialisation · Sales in main European markets increased 99% to £1.5 million · H2 sales in main European markets increased 117% to £880,000 · H2 sales in the UK increased 174% · Market share in UK increased from 4.7% in 2009 to 8.9% in 2010 · Field force expanded to 4 in the UK (2009: 1) and 2 in Germany (2009: nil) Aorfix™ Rest of World Commercialisation · Distribution agreement signed for $100 million Japanese market · Sales in ROW markets rose 2% despite adverse economic conditions affecting sales in some markets, including Greece Aorfix™ U.S. trial and PMA submission · Five out of six FDA PMA modules submitted; three approved · Submission of final clinical module expected in H1 2011 as planned Other · Management team further strengthened · Stent graft production started at Prestwick facility, supported by a Scottish Enterprise grant · Two major development projects with respect to Aorfix™ initiated Financial Highlights · Revenues up 28% to £3.0 million (2009: £2.4 million) · Gross margin increased to 46% (2009: 42%) · Operating expenses increased 17% to £10.1 million (2009: £8.7 million): · Investment in sales and marketing up 52% to £2.3 million (2009: £1.5 million) · Investment in R&D up 11% to £5.2 million (2009: £4.7 million) · Net cash outflow from operating activities grew 15% to £7.6 million (2009: £6.7 million) · Total loss for the year rose 27% (16% for continuing business) to £7.9 million (2009: £6.2 million and £6.8 million for continuing business) · £13.3 million (£12.1 million net of expenses) successfully raised in February 2010 from placing and subscription of shares Post Period Events · Two-tranche placing and subscription to raise up to £25.3 million announced. First tranche of £11.1 million (£10.4 million net of expenses) to be received following shareholder approval; second tranche of £14.2 million (£13.6 million net of expenses) to be received following FDA approval of Aorfix™ · Sufficient funds to replicate UK model in other European countries and to finance the Company's long term business plans in U.S. and Japan

The news is finally out...check there website!.......They need to raise 27 million! Issue of equity to raise up to £27.5 million to fund U.S. approval and launch of Aorfix™ London, UK, 20 April 2011 - Lombard Medical Technologies PLC (AIM: LMT), the specialist medical devices company, today announced that it proposes to raise up to £25.3 million (before expenses) through a placing and subscription arranged on the Company's behalf by Evolution Securities Limited and Eden Financial Limited. As part of the subscription, Abingworth LLP and MVM Life Science Partners LLP, both specialist healthcare investors, have committed to invest, in aggregate, up to £13.0 million. The placing and subscription will be issued and admitted to trading in two tranches. In addition, qualifying shareholders and qualifying employees are being invited to participate in the fundraising pursuant to an offer that may raise up to an additional £2.2 million (before expenses). The Company will raise up to £13.3 million (before expenses) through the first tranche of the fundraising. The Company will raise a further £14.2million (before expenses) through the second tranche of the fundraising subject to certain milestones and conditions being achieved (or waived by certain of the investors). The Directors believe the net proceeds of the first fundraising and the second fundraising will, assuming that these are received in full, give the Company sufficient cash to fund it through to cash flow break even.

Perhaps they are waiting for the 4th and 5th modules approvals before announcing their result?. Either way it will be late April soon, so i suspect another amend on their website to reflect this!